FDA Approves Promega Test as Keytruda Companion

The OncoMate MSI Dx Analysis System identifies MSI-high solid tumours that may respond to Merck's Keytruda.

Updated on Nov. 13, 2026 in Cancer

Bold flat-color editorial illustration of unlabeled glass sample vials with amber liquid in a metal rack against a cream background.
The FDA approved Promega's OncoMate MSI Dx Analysis System on Tuesday as a companion diagnostic identifying MSI-high solid tumours that may respond to Merck's Keytruda. AI Illustration. Upload story photo >

The U.S. Food and Drug Administration approved Promega's OncoMate MSI Dx Analysis System as a companion diagnostic for Keytruda in microsatellite instability-high (MSI-H) solid tumours. The approval follows China's NMPA granting Promega's MSI technology a similar companion diagnostic approval for the same indication.

Why it matters

Companion diagnostics help clinicians identify which patients are most likely to benefit from a specific therapy, so an approved test for Keytruda in MSI-H tumours could guide treatment decisions across multiple cancer types. The approval was supported through a collaboration between Promega and Merck.

The OncoMate MSI Dx Analysis System is a PCR-based assay that evaluates microsatellite instability status in solid tumour tissue. The source does not report clinical sensitivity or specificity figures, and the number of patients expected to be identified by the test remains unstated.

The players

Promega Corporation

Promega is a life sciences company that develops molecular biology tools, with a portfolio of over 4,000 products, and it developed the OncoMate MSI Dx Analysis System.

Merck

Merck is a global pharmaceutical company that markets Keytruda, the cancer immunotherapy for which the diagnostic is approved as a companion test.

The details

The OncoMate MSI Dx Analysis System was previously cleared by the FDA for identifying colorectal cancer patients who may benefit from additional testing for Lynch syndrome and was approved as a companion diagnostic for patients with microsatellite stable endometrial carcinoma treated with Keytruda plus Lenvima. Keytruda is indicated for adult and paediatric patients with unresectable or metastatic MSI-H or mismatch repair deficient cancer who have progressed after prior treatment and have no satisfactory alternative options.

Timeline

  1. FDA approval of OncoMate MSI Dx as a Keytruda companion diagnostic was announced on November 13, 2026.

  2. Earlier FDA clearance for Lynch syndrome screening and approval for MSS endometrial carcinoma preceded this approval; the source does not state those dates.

Cancer Testing Landscape

This approval extends the OncoMate platform, first cleared by the FDA for Lynch syndrome screening in colorectal cancer, into biomarker-guided immunotherapy selection. It follows a pattern in which MSI testing moves from hereditary cancer screening toward tumour-agnostic treatment decisions.

Patients with MSI-high solid tumours may have a clearer testing pathway to determine whether Keytruda is an option for their treatment. Clinicians gain an FDA-approved tool to confirm MSI status before prescribing this immunotherapy.

The takeaway

Biomarker testing such as MSI analysis can determine eligibility for immunotherapy across different cancer types, so patients with advanced solid tumours may ask their oncologist whether MSI status has been tested.

Further reading

For more on how biomarker testing shapes treatment choices, explore Cancer coverage on Wisevoter.

Source note: This article includes information reported by Pharmabiz.